Lutronic and Syneron-Candela Settle Lawsuit

Syneron Medical Ltd and Candela Corporation, and Lutronic Corp and Lutronic Aesthetics Inc, announce that they have entered into a mutually agreeable comprehensive settlement agreement ending the patent disputes between the companies.

Terms of the settlement agreement were not disclosed.

The mutually agreed-upon settlement, limited to Lutronic, protects Candela’s investment in Profound and its patented long pulse and temperature-controlled technology today and in the future. The settlement, through a sublicense from Syneron-Candela, allows Lutronic to market its product in the short pulse category, protecting Candela’s investment in the development of products in the long pulse category with a thermocouple.

For more information, read the full news release at

Profound Microneedling Device Named “New Treatment of the Year”


Candela Corporation announces that the Profound microneedling treatment has been named “New Treatment of the Year” by The Global Aesthetic Awards, also known as MyFaceMyBody Awards USA.

The Profound system is a radiofrequency (RF) microneedling device that is designed to use real-time temperature control to yield predictable outcomes and is FDA-cleared for the treatment of facial wrinkles and improvements in the appearance of cellulite.

MyFaceMyBody Awards celebrates the innovation and customer excellence within the aesthetics industry. The awards honor leaders in aesthetics and brands for their product innovation and popularity. Hundreds of applications from across the United States are received, and category winners are elected from consumer and industry votes, according to a media release from Candela.

“We are pleased to provide solutions for the treatments and outcomes consumers and the industry are seeking. Over 3 million Americans had a nonsurgical aesthetic treatment in 2017, and this award is a testament to the growing demand for the Profound treatment’s clinically proven results and the patient satisfaction achieved with the device’s unique patented technology,” says Mary Trout, chief commercial officer, Candela, in the release.

“The Profound treatment is clinically proven to create up to five times the elastin, twice the collagen, and increased hyaluronic acid during nonsurgical treatment, enabling practitioners to offer long lasting outcomes and provide their patients with a trusted, natural alternative to dermal injectables and surgery.”

The Profound system uses patented technology to deliver RF energy to induce the body’s natural healing response to regenerate new collagen, elastin and hyaluronic acid, without toxins or fillers. The real-time and continuously monitored, temperature-controlled device allows practitioners to determine how much energy is delivered, as well as achieve and maintain a therapeutic temperature level, the release continues.

[Source(s): Candela, PR Newswire]

Candela Partners with the Vascular Birthmarks Foundation To Provide Laser Treatments

Candela Corporation announces it will be partnering with the Vascular Birthmarks Foundation (VBF) to provide pro-bono Vbeam laser treatments to children and adults with birthmarks, port wine stains and other vascular related skin conditions as a kickoff to the VBF 18th Annual Conference.

The treatments will be performed at the Laser & Skin Surgery Center of New York in Manhattan on Friday, October 5, by the center’s director, Dr Roy Geronemus.

“Candela is committed to developing and enhancing innovative technological solutions that change lives. Our partnership with the Vascular Birthmarks Foundation and Dr Roy Geronemus reflects this commitment,” states Geoffrey Crouse, chief executive officer of Candela.

To read the full press release, visit

Patent Infringement Suits Filed Against 18 Manufacturers and Distributors of Fractional RF Microneedle Systems

Syneron Medical Ltd and its subsidiary Candela Corporation (collectively, Syneron Candela) and Massachusetts General Hospital (MGH) filed patent infringement complaints against 18 manufacturers and distributors of fractional RF micro-needle dermatological treatment systems in both the U.S. International Trade Commission in Washington, D.C. and in federal district court.

The accused infringing products include Secret RF by ilooda Co., Ltd. and Cutera, Inc.; Fraxis Duo by ilooda Co., Ltd., Emvera Technologies, LLC and Rohrer Aesthetics, LLC; Fractora by Invasix Ltd., Invasix, Inc. and InMode MD Ltd.; Legend Pro by Lumenis Ltd and Pollogen Ltd; 3DEEP by EndyMed Medical Ltd. and EndyMed Medical Inc.; INTRAcel by Jeisys Medical, Inc. and Perigee Medical LLC; Infini by Lutronic, Corp. and Lutronic, Inc.; and Vivace by Sung Hwan E&B Co. Ltd, Aesthetics Biomedical, Inc. and Cartessa Aesthetics LLC.